Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study

Hepatitis

Development of Hepatocellular Carcinoma by Patients Aged 75-84 with Chronic Hepatitis C Treated with Direct-acting Antivirals

J Infect Dis.

Ogawa E, Nomura H, Nakamuta M, Furusyo N, Kajiwara E, Dohmen K, Kawano A, Ooho A, Azuma K, Takahashi K, Satoh T, Koyanagi T, Ichiki Y, Kuniyoshi M, Yanagita K, Amagase H, Morita C, Sugimoto R, Kato M, Shimoda S, Hayashi J, Kyushu University Liver Disease Study (KULDS) Group.

doi: 10.1093/infdis/jiaa359.

Hepatitis

Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis

J Hepatol.

Ji F, Yeo YH, Wei MT, Ogawa E, Enomoto M, Lee DH, Iio E, Lubel J, Wang W, Wei B, Ide T, Preda CM, Conti F, Minami T, Bielen R, Sezaki H, Barone M, Kolly P, Chu PS, Virlogeux V, Eurich D, Henry L, Bass MB, Kanai T, Dang S, Li Z, Dufour JF, Zoulim F, Andreone P, Cheung RC, Tanaka Y, Furusyo N, Toyoda H, Tamori A, Nguyen MH

doi: 10.1016/j.jhep.2019.04.017.

Hepatitis

Sofosbuvir-Based Therapy in Hepatitis C Virus-infected Cancer Patients: A Prospective Observational Study

Am J Gastroenterol.

Torres HA, Economides MP, Angelidakis G, Hosry J, Kyvernitakis A, Mahale P, Jiang Y, Miller E, Blechacz B, Naing A, Samaniego F, Kaseb A, Raad II, Granwehr BP

doi: 10.1038/s41395-018-0383-2.

Hepatitis

Effectiveness and Safety of Sofosbuvir/Velpatasvir/ Voxilaprevir in Patients with Chronic Hepatitis C Previously Treated with DAAs

J Hepatol.

Llaneras J, Riveiro-Barciela M, Lens S, Diago M, Cachero A, García-Samaniego J, Conde I, Arencibia A, Arenas J, Gea F, Torras X, Luis Calleja J, Antonio Carrión J, Fernández I, María Morillas R, Miguel Rosales J, Carmona I, Fernández-Rodríguez C, Hernández-Guerra M, Llerena S, Bernal V, Turnes J, González-Santiago JM, Montoliu S, Figueruela B, Badia E, Delgado M, Fernández-Bermejo M, Iñarrairaegui M, Manuel Pascasio J, Esteban R, Mariño Z, Buti M

doi: 10.1016/j.jhep.

Gastrointestinal CancerHepatitis

No difference in hepatocellular carcinoma risk between chronic hepatitis B patients treated with entecavir versus tenofovir

Gut.

Su F, Ioannou GN, Berry K

doi: 10.1136/gutjnl-2019-319867.

HepatitisHepatology

Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)

Am J Gastroenterol.

Huang CF, Lai HC, Chen CY, Tseng KC, Kuo HT, Hung CH, Wang JH, Chen JJ, Lee PL, Chien RN, Yang CC, Lo GH, Tai CM, Lin CW, Kao JH, Liu CJ, Liu CH, Yan SL, Bair MJ, Lin CY, Su WW, Chu CH, Chen CJ, Tung SY, Lo CC, Cheng PN, Chiu YC, Wang CC, Cheng JS, Tsai WL, Lin HC, Huang YH, Yeh ML, Huang JF, Dai CY, Chuang WL, Tsai PC, Peng CY, Yu ML

doi: 10.14309/ajg.0000000000000606.

HepatitisHepatology

Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous daa failure

J Hepatol.

Degasperi E, Spinetti A, Lombardi A, Landonio S, Rossi MC, Pasulo L, Pozzoni P, Giorgini A, Fabris P, Romano A, Lomonaco L, Puoti M, Vinci M, Gatti F, Carolo G, Zoncada A, Bonfanti P, Paolo Russo F, Aghemo A, Soria A, Centenaro R, Maggiolo F, Rovere P, Pasin F, Paon V, Faggiano G, Vario A, Grossi G, Soffredini R, Carriero C, Paolucci S, Noventa F, Alberti A, Lampertico P, Fagiuoli S, NAVIGATORE-Lombardia.

doi: 10.1016/j.jhep.2019.07.020.

Hepatitis

Patient-reported symptoms during and after direct acting antiviral therapies for chronic hepatitis C: The PROP UP Study

J Hepatol.

Evon DM, Sarkar S, Amador J, Lok AS, Sterling RK, Stewart PW, Reeve BB, Serper M, Reau N, Rajender Reddy K, Di Bisceglie AM, Nelson DR, Golin CE, Lim JK, Fried MW

doi: 10.1016/j.jhep.2019.04.016.

Hepatitis

Disease Progression in Patients With Hepatitis C Virus Infection Treated With Direct-acting Antiviral Agents

Clin Gastroenterol Hepatol.

Mendizabal M, Piñero F, Ridruejo E, Wolff FH, Anders M, Reggiardo V, Ameigeiras B, Palazzo A, Alonso C, Schinoni MI, Videla Zuain MG, Tanno F, Figueroa S, Santos L, Peralta M, Soza A, Vistarini C, Adrover R, Fernández N, Perez D, Hernández N, Estepo C, Bruno A, Descalzi V, Sixto M, Borzi S, Cocozzella D, Zerega A, de Araujo A, Varón A, Rubinstein F, Cheinquer H, Silva M

doi: 10.1016/j.cgh.2020.02.044.

Related content

Development of Hepatocellular Carcinoma by Patients Aged 75-84 with Chronic Hepatitis C Treated with Direct-acting Antivirals

Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis

Sofosbuvir-Based Therapy in Hepatitis C Virus-infected Cancer Patients: A Prospective Observational Study

Effectiveness and Safety of Sofosbuvir/Velpatasvir/ Voxilaprevir in Patients with Chronic Hepatitis C Previously Treated with DAAs

No difference in hepatocellular carcinoma risk between chronic hepatitis B patients treated with entecavir versus tenofovir

Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)

Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous daa failure

Patient-reported symptoms during and after direct acting antiviral therapies for chronic hepatitis C: The PROP UP Study

Disease Progression in Patients With Hepatitis C Virus Infection Treated With Direct-acting Antiviral Agents